Plate Nº 47 · recorded November 18, 2026
Health & Medicine ResearchReported finding
Two Men Hospitalized With Psychosis After Stopping GLP-1 Drug
Two men developed mania or psychosis within weeks of abruptly stopping tirzepatide. Researchers call the timing suspicious but stress two cases prove nothing.
By Marcus Bennett3 min read676 words
In brief
- Two men, aged 61 and 52, were hospitalized in October 2025 after abruptly stopping tirzepatide.
- One patient developed Cotard delusion, hallucinations and paranoia; the other had a manic episode after losing 100 pounds in six months.
- A European database previously logged 481 psychiatric events tied to semaglutide, liraglutide and tirzepatide, just over 1% of reports.
- The findings were published in The Primary Care Companion for Central Nervous System Disorders.

Two men were hospitalized in October 2025 with severe psychiatric symptoms — mania in one case, hallucinations and a rare "walking corpse" delusion in the other — within weeks of abruptly stopping the GLP-1 drug tirzepatide, sold as Mounjaro and Zepbound.
Doctors reported both cases in the peer-reviewed journal The Primary Care Companion for Central Nervous System Disorders. The reports do not prove the drug discontinuation caused the episodes. But the timing, the authors write, points to a pattern clinicians should not ignore.
What happened to the two patients?
The first patient, a 61-year-old man, arrived at hospital with worsening confusion and erratic behavior that appeared to come out of nowhere. He reported low mood, deepening depression, paranoia, and both auditory and visual hallucinations. He had also developed Cotard delusion — a rare psychiatric condition in which a person believes they are dead, or that parts of their body are missing or no longer working.
He had stopped tirzepatide in August 2025 because of nausea, roughly two months before his hospitalization.
The second patient, a 52-year-old man, entered the same hospital in the same month with erratic behavior and mood swings. Doctors diagnosed a manic episode: his speech was hyperverbal and disorganized, and he showed grandiosity, impulsivity, and irritability. He had quit tirzepatide abruptly one month earlier, after losing 100 pounds over six months.
Complicating factors were present. In the weeks before his hospital visit, the second patient had increased his cannabis use, which is a known risk factor for psychosis. His vitamin B12 levels were also low, pointing to nutritional deficits. He was transferred to a psychiatric facility for further care.
Does stopping tirzepatide actually cause psychiatric symptoms?
The honest answer: nobody knows yet. Two case reports cannot establish cause and effect. Both patients also had prior psychiatric diagnoses — depression in one, anxiety in the other — which may have shaped their symptoms.
Still, the authors argue the mechanism is biologically plausible. GLP-1 receptors — the molecular docking sites the drug targets — exist not only in the gut but also in the brain, and evidence suggests these medications can cross the blood-brain barrier, the protective filter that shields the brain from most circulating substances. What the drug does once inside the brain remains largely unknown.
"While likely not the sole factor, it is plausible that discontinuation of a GLP-1 receptor agonist may contribute to acute-onset mood or psychotic symptoms in a select population of at-risk patients," the authors write, "including patients with nutritional deficiencies associated with, or exacerbated by, GLP-1 use, such as the second patient with a low vitamin B12 level."
How rare are psychiatric events on GLP-1 drugs?
These outcomes are uncommon, but they are not undocumented. A few years ago, a European drug database recorded 481 psychiatric events associated with three GLP-1 drugs: semaglutide, liraglutide, and tirzepatide. Those events made up just over 1 percent of all reports tied to the drugs — but researchers argued then that the serious, sometimes life-threatening nature of the episodes justified further study.
The new case reports extend that concern from taking the drugs to stopping them. "While the neuropsychiatric effects of GLP-1 agonist treatment are increasingly recognized… the psychiatric implications of discontinuing these medications remain poorly characterized," the authors write. "Acute-onset mood or psychotic symptoms following GLP-1 receptor agonist discontinuation may represent an underrecognized clinical phenomenon."
What should prescribers and patients take from this?
The authors' practical message is simple: prescribers should ask about recent GLP-1 medication changes when a patient presents with sudden-onset mood or psychotic symptoms. Patients should not stop tirzepatide abruptly without talking to their doctor, particularly if they have a psychiatric history or nutritional deficiencies.
As millions of people take these medications, researchers keep uncovering rare side effects. GLP-1 drugs carry substantial benefits — and the more clinicians and patients know about the potential downsides, the better prepared they are when something goes wrong.
Two cases do not settle the question, but they put prescribers on notice.
via sciencealert.com (Source)
More from Marcus Bennett
Show full bio
News editor covering regulation, policy and their impact on general science news at SciBeat.
493 articles
Nearby plates
- Supernatural delusions drove 177 psychedelic-linked killings, studies find
- GLP-1 overdoses hit 25,000 a year as weight-loss drug use surges
- Why Weight-Loss Drugs Fail Some People — and What Can Be Done
- Ozempic and Wegovy Linked to Rare Risk of Sudden Vision Loss
- Semaglutide Linked to 21% Lower Psychiatric Hospitalization Risk